Here's why IP Group looks undervalued. Three brokers take a deep dive

IP Group reported a 13% rise in NAV per share to 110.4p for the year to Dec-2025, driven by a licensing deal tied to Pfizer’s $10bn acquisition of Metsera. The shares jumped 11% to 54.7p and three brokerages maintained 'buy' ratings following the strong full-year results. The deal and NAV uplift materially improve near-term valuation sentiment for the stock.

Analysis

This result should be read as a liquidity and valuation signal to the market for early-stage IP investors rather than a one-off valuation bump. When an early-stage commercialization vehicle demonstrates that its portfolio can generate tradeable licensing outcomes, it short-circuits the usual long tail between academic IP and industrial monetisation — that encourages buyers (strategic acquirers, royalty financiers) to bid up similar assets, compressing expected hold times from years to quarters and increasing realized NAV volatility in the near term.

Secondary winners will be intermediaries and capital providers that bridge university tech transfer to industry — royalty funds, SPVs and boutique M&A advisors — because the path from invention to cash becomes demonstrably bankable, lifting multiples on recurring royalty streams. Conversely, small private biotechs that relied on long-hold strategic exits may see acquisition windows narrow and price discipline increase, pressuring those that are pre-proof-of-concept.

Key risks are concentration and event risk: a portfolio re-rating driven by a single material monetisation can reverse if counterparties reprice, litigation arises around IP scope, or royalty terms are renegotiated. Time horizons matter: market reaction is immediate (days), meaningful revaluation of similar vehicles plays out over 3–12 months as buyers re-underwrite asset economics, and ultimate cash realisation still sits on a multi-year timeline tied to long-tail royalty receipts and patent lifecycles.

Key Decisions for Investors

• Long IPO.L (IP Group) equity, 6–12 month holding period, position size 2–4%: asymmetric payoff if additional licensing/exit activity follows; set tactical stop at 15% from entry to limit reversal from event-driven profit-taking.
• Buy a 12-month IPO.L call spread (buy 25% OTM, sell 50% OTM) sized so premium = 1–2% of portfolio to capture further re-rating with defined downside; target 3–5x return if market extends rerating to comparable IP managers.
• Pair trade: long IPO.L / short FTSE SmallCap growth ETF (6–12 months): use 1:0.7 notional to isolate rerating of IP monetisation vs. broad small-cap sentiment; expected carry-positive if sector-specific M&A momentum continues, risk concentrated to macro risk-off which would hurt both legs.
• Hedge tail risk with cheap protection: buy 3–6 month puts on IPO.L (10–15% OTM) funded by selling nearer-dated calls (3 months) to protect downside from a narrative reversal triggered by litigation or a failed counterparty transaction.
• Event hedge on big pharma exposure: buy 3–6 month PFE calls (small allocation) as a tactical hedge to capture continued strategic M&A appetite in obesity/adjacent therapeutic areas; this offsets downside if market rotates to large-cap pharma winners and squeezes small-cap IP investors.